Rakesh Kumar Dixit

Rakesh Kumar Dixit

Auto-generated profile, based on publicly available information

Rakesh Kumar Dixit

Lucknow, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SKSantosh Kumar
Santosh Kumar
RDRakesh Dixit
Rakesh Dixit
SKSaurabh Karmakar
Saurabh Karmakar
SPSayan Paul
Sayan Paul
Cyclophosphamide therapy may rarely cause pigmentation of the nails which is of different patterns. We report a patient who developed pigmentation of nails after six cycles of cyclophosphamide, methotrexate, and 5-flourouracil chemotherapy, each repeated after 28 days for breast cancer. The patient developed nail pigmentation that started proximally and spread distally and involved all the nails of both hands and feet except the second and third toenails of right foot. Using Naranjo ADR Probability Scale, the case revealed a "probable" association with cyclophosphamide.

1 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
EBEmily E. Bosco
Emily E. Bosco
RCR. James Christie
R. James Christie
RCRosa Carrasco
Rosa Carrasco
DSDarrin Sabol
Darrin Sabol
JZJiping Zha
Jiping Zha
DTDavid A. Tice
David A. Tice
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Emily E. Bosco1, R. James Christie2, Rosa Carrasco1, Darrin Sabol1, Jiping Zha3, 8, Karma DaCosta3, Lee Brown4, Maureen Kennedy1, John Meekin1, Sandrina Phipps2, Joanne Ayriss2, 6, Qun Du2, Binyam Bezabeh2, 7, Partha Chowdhury2, 9, Shannon Breen1, Cui Chen1, Molly Reed5, MaryJane Hinrichs5, Haihong Zhong1, Zhan Xiao1, Rakesh Dixit5, Ronald Herbst1 and David A. Tice1 1Oncology Research, MedImmune, LLC, Gaithersburg, Maryland, United States of America 2Antibody Discovery and Protein Engineering, MedImmune, LLC, Gaithersburg, Maryland, United States of America 3Pathology, MedImmune, LLC, Gaithersburg, Maryland, United States of America 4Pathology, MedImmune, Ltd, Cambridge, United Kingdom 5Biologics Safety Assessment, MedImmune, LLC, Gaithersburg, Maryland, United States of America 6Department of Global Biotherapeutics, Pfizer, Cambridge, Massachusetts, United States of America 7Research, Salubris Biotherapeutics, Gaithersburg, Maryland, United States of America 8Translational Sciences, NGM Biopharmaceuticals, South San Francisco, California, United States of America 9Biologics Discovery, Sanofi Genzyme, Cambridge, MA, United States of America *These authors contributed equally to this work Correspondence to: Emily E. Bosco, email: boscoe@medimmune.com Keywords: GFRA1; antibody-drug conjugate (ADC); pyrrolobenzodiazepine (PBD); anti-tumor activity; breast cancer Received: January 12, 2018 Accepted: April 05, 2018 Published: May 01, 2018 ABSTRACT Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately lead to improved tumor-targeted treatment options, particularly for subsets of breast cancer patients with unmet needs. Using an unbiased genomics approach to uncover membrane-localized tumor-associated antigens (TAAs), we have identified glial cell line derived neurotrophic factor (GDNF) family receptor α 1 (GFRA1) as a breast cancer TAA. Immunohistochemistry (IHC) revealed that GFRA1 displays a limited normal tissue expression profile coupled with overexpression in specific breast cancer subsets. The cell surface localization as determined by fluorescence-activated cell sorting (FACS) and the rapid internalization kinetics of GFRA1 makes it an ideal target for therapeutic exploitation as an antibody-drug conjugate (ADC). Here, we describe the development of a pyrrolobenzodiazepine (PBD)-armed, GFRA1-targeted ADC that demonstrates cytotoxicity in GFRA1-positive cell lines and patient-derived xenograft (PDX) models. The safety profile of the rat cross-reactive GFRA1-PBD was assessed in a rat toxicology study to find transient cellularity reductions in the bone marrow and peripheral blood, consistent with known off-target effects of PBD ADC’s. These studies reveal no evidence of on-target toxicity and support further evaluation of GFRA1-PBD in GFRA1-positive tumors.

16 August 2016 in Integrative Medicine Research
Verified
Journal Article
Open access
PDF file
VAVaseem Ahmad Ansari
Vaseem Ahmad Ansari
MAMUHAMMAD ARIF
MUHAMMAD ARIF
SHSarfaraj Hussain
Sarfaraj Hussain
HSHefazat Hussain Siddiqui
Hefazat Hussain Siddiqui
RDRakesh Kumar Dixit
Rakesh Kumar Dixit
Background: The fruit Terminalia belerica is a rich source of vitamins, acids, and nutraceuticals which have free radical scavenging activity. Thus, the ethanolic extract of fruit and its isolated compound (Tb-01) were intended to estimate antiplatelet and antioxidant activities. Methods: The ethanolic extract was submitted to Si-gel CC and the compound was isolated. The compound Tb-01 was characterized as benzoyl-β-D-(4′→10″ geranilanoxy)-pyranosides on the basis of spectral data [ultra violet (UV), infrared (IR), 1H nuclear magnetic resonance (NMR), 13C NMR, and Mass Spectroscopy] and chemical analyses. The ethanolic extract and Tb-01 at different concentrations were in vitro screened for antiplatelet and antioxidant activity. The antiplatelet activity was carried out by using platelet rich plasma prepared by centrifugation of rabbit whole blood (containing 0.9% sodium citrate as anticoagulant) and antioxidant activity using 1,1-diphenyl-2-picrylhydrazyl, reducing power, and nitric oxide anion scavenging activity models. Results: The compound Tb-01 was an amorphous brownish powder, yield 0.64% (w/w), melting point 105–110 °C, Retardation factor/Retention Value (Rf value) at 0.42 in methanol:chloroform (20:80) solvent system, UV absorption maxima at 243 nm, and molecular peak [M + H]+ at 394.15 m/z. It was observed that the ethanolic extract and Tb-01 at different concentrations showed significant antiplatelet and antioxidant activity. The antioxidant activity, like scavenging of 1,1-diphenyl-2-picrylhydrazyl radicals, nitric oxide radical, and reductive power were found to be concentration-dependent and increased when increasing amounts of sample were used. Conclusion: Mass spectra and 1H NMR confirmed the isolated compound structure which was supported by 13C NMR and IR spectra. Tb-01could be promising for future applications in the treatment of blood clots, pulmonary embolism, and other related diseases.

1 January 2012 in Indian Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SKSaurabh Karmakar
Saurabh Karmakar
RDRakesh Dixit
Rakesh Dixit
ANAlok Nath
Alok Nath
SKSantosh Kumar
Santosh Kumar
SKShilpi Karmakar
Shilpi Karmakar
The war against cancer has seen a proliferation in armamentarium over the last decades. A new antineoplastic agent, trastuzumab, was synthesized in 1991 and gained United States Food and Drug Administration approval in 1998 for treatment of metastatic breast cancer. Cardiotoxicity manifesting as dilated cardiomyopathy is a rarely reported adverse effect of trastuzumab. We hereby report a case of dilated cardiomyopathy, which occurred following trastuzumab chemotherapy in a 32-year-old female. The patient responded to discontinuation of trastuzumab and standard medical treatment. Extensive search of Indian literature revealed no reported case of dilated cardiomyopathy occurring due to trastuzumab.

2 May 2017 in Asian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
DSDheeraj Kumar Singh
Dheeraj Kumar Singh
NKNarendra Kumar
Narendra Kumar
ASAnjula Sachan
Anjula Sachan
PLPreet Lakhani
Preet Lakhani
STSachin Tutu
Sachin Tutu
RDRakesh Kumar Dixit
Rakesh Kumar Dixit
Background: The prevalence of obesity is increasing worldwide. Obesity has a direct correlation with insulin resistance and various cardiovascular diseases like hypertension,dyslipidaemia etc. Hypertension is considered as a major independent risk factor for coronary disease and stroke for all age, race & sex groups. Gymnema sylvestre and Acorus calamus are two well known herbs of traditional system of medicine effective in various diseases.Aims and Objectives: The present study was designed to explore the antihypertensive effects of Gymnema sylvestre (GS) and Acorus calamus (AC), individually as well as in combination, in wistar rats.Materials and Methods: Female wistar rats, weighing between 150- 200 g, were included in the study. They were divided into eight groups with six rats in each group. High Fat diet (HFD) was used to induce hypertension in all the groups except group 1 which was fed with normal rodent diet. Drugs were given to the rats by oral feeding cannula.Results: Feeding rats with HFD for 4 weeks lead to signifi cant increase in the mean systolic blood pressure. Both Gymnema sylvestre and Acorus calamus signifi cantly reduced the systolic blood pressure. Combination of both these (Gymnema sylvestre 200mg/kg and Acorus calamus 200mg/kg) as well as Gymnema sylvestre (200mg/kg) individually has an effect comparable to Amlodipine. Individual drugs had no signifi cant effect on heart rate while the combination of these two drugs signifi cantly reduced the heart rate.Conclusions: The present study concludes that extracts of Gymnema sylvestre and Acorus calamus has a signifi cant antihypertensive action in rodent model of hypertension. Combination is found superior to the individual drugs.Asian Journal of Medical Sciences Vol.8(3) 2017 11-15

24 January 2020 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
GAGarima Adhaulia
Garima Adhaulia
DSDivya Singh
Divya Singh
AVAjay Kumar Verma
Ajay Kumar Verma
ASArpita Singh
Arpita Singh
RNRajendra Nath
Rajendra Nath
RDRakesh K. Dixit
Rakesh K. Dixit
Background: Asthma is a chronic inflammatory disease requiring long term treatment. For an effective control of asthma symptoms background knowledge of the prescribing pattern of anti-asthmatic drugs is a must.Methods: A prospective, observational study was conducted in the Department of Respiratory Medicine OPD, King George's Medical University, Lucknow. 114 patients of asthma were recruited for the study. A case report form was filled from patient’s prescription containing the demographic details of the patients, presenting complaints, investigations and drugs prescribed along with their dose, duration, frequency, route of administration.Results: 114 patients’ prescriptions were assessed which showed average number of drugs per prescription - 3.22. 42.8% and 50% of the drugs were prescribed in accordance with World Health Organization model list of essential medicines and National list of essential medicines. Short acting β2 agonist (salbutamol), 61.4% was the most commonly and frequently prescribed single anti asthmatic drug. Combination of inhaled corticosteroid and long acting β2 agonist, 86.8% was the most commonly prescribed fixed dose combination anti asthmatic drug. Inhalational route (75%) was the most preferred one over oral route (25%).Conclusions: Asthma being a chronic disease requires prolonged treatment which imposes economic burden on the patients. Judicious prescription of drugs not only improves the patient clinically but also removes the unnecessary burden. Data obtained from these studies can be used as a guide to make future decisions regarding standard prescription.